Malignant Neoplasm of the Bladder B029

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/m/malignant-neoplasm-bladder-b029-c67-d090

Last amended

Rulebase for malignant neoplasm of the bladder

<h5><strong>Current RMA Instruments</strong></h5><table border="1" cellpadding="1" cellspacing="1"><tbody><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2019/dd1356c9a9/083.pdf&quot; target="_blank">Reasonable Hypothesis</a></address></td><td>83<span> of 2019</span></td></tr><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2019/1080f2ea4e/084.pdf&quot; target="_blank">Balance of Probabilities</a></address></td><td><span>84 of 2019</span></td></tr></tbody></table><h5>Changes from previous Instruments</h5><p><drupal-media data-entity-type="media" data-entity-uuid="aa2344ff-d5f1-4a69-a5cf-46fd97ee1de8" data-view-mode="wysiwyg"></drupal-media></p><h5>ICD Codes</h5><ul><li>ICD-9-CM: 188,233.7</li><li>ICD-10-AM: C67, D09.0</li></ul><h5>Brief description</h5><p>This is a primary cancer of the lining of the bladder.</p><h5>Confirming the diagnosis</h5><p>The diagnosis requires confirmation by histology.</p><p>The relevant medical specialist is a urologist.</p><h5>Diagnoses covered by SOP</h5><ul><li>Adenocarcinoma of the bladder</li><li>Carcinoma-in-situ of the bladder</li><li>Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder</li><li>Squamous cell carcinoma of the bladder</li><li>Transitional cell carcinoma of the bladder</li><li>Undifferentiated carcinoma of the bladder</li></ul><h5>Conditions that may be covered by SOP (further information required)</h5><ul><li>Bladder cancer</li></ul><h5>Conditions excluded from SOP</h5><ul><li>Carcinoid of the bladder<span><sup>#</sup></span></li><li>Hodgkin's lymphoma of the bladder*</li><li>Malignant neoplasm of the prostate*</li><li>Malignant neoplasm of the urethra*</li><li>Non-Hodgkin lymphoma of the bladder*</li><li>Soft tissue sarcoma of the bladder*</li></ul><p>* another SOP applies</p><p><span><sup>#</sup></span>Non-SOP condition</p><h5>Clinical onset</h5><p>The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.</p><h5>Clinical worsening</h5><p>The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. </p><p> </p>

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder

A renal transplant

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/renal-transplant

Last amended

An indwelling bladder catheter

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/indwelling-bladder-catheter

Last amended

Atomic radiation

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/atomic-radiation

Last amended

Cigar smoking

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/cigar-smoking

Last amended

Cigarette smoking

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/cigarette-smoking

Last amended

Consuming Aristolochia fangchi as a contaminant of herbal weight loss medication

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/consuming-aristolochia-fangchi-contaminant-herbal-weight-loss-medication

Last amended

Consuming phenacetin

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/consuming-phenacetin

Last amended

Diabetes mellitus

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/diabetes-mellitus

Last amended

Dialysis for a chronic renal condition

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/dialysis-chronic-renal-condition

Last amended

Exposure to aromatic amines

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/exposure-aromatic-amines

Last amended

Exposure to arsenic as specified

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/exposure-arsenic-specified

Last amended

Exposure to fumes containing high concentrations of PAHs

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/exposure-fumes-containing-high-concentrations-pahs

Last amended

Exposure to tetrachloroethylene or dry cleaning solvents

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/exposure-tetrachloroethylene-or-dry-cleaning-solvents

Last amended

Infection with Schistosoma haematobium

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/infection-schistosoma-haematobium

Last amended

Inhaling air containing PAHs

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/inhaling-air-containing-pahs

Last amended

Kidney or bladder stone

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/kidney-or-bladder-stone

Last amended

No appropriate clinical management for malignant neoplasm of the bladder

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/no-appropriate-clinical-management-malignant-neoplasm-bladder

Last amended

Pipe smoking

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/pipe-smoking

Last amended

Smoking tobacco products - material contribution

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/smoking-tobacco-products-material-contribution

Last amended

Therapeutic radiation to the pelvic region

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/therapeutic-radiation-pelvic-region

Last amended

Treatment with systemic cyclophosphamide or systemic ifosfamide

Current RMA Instruments
Reasonable Hypothesis
83 of 2019
Balance of Probabilities
84 of 2019
Changes from previous Instruments

ICD Codes
  • ICD-9-CM: 188,233.7
  • ICD-10-AM: C67, D09.0
Brief description

This is a primary cancer of the lining of the bladder.

Confirming the diagnosis

The diagnosis requires confirmation by histology.

The relevant medical specialist is a urologist.

Diagnoses covered by SOP
  • Adenocarcinoma of the bladder
  • Carcinoma-in-situ of the bladder
  • Malignant neoplasm of the ureteric orifice or urethral orifice of the bladder
  • Squamous cell carcinoma of the bladder
  • Transitional cell carcinoma of the bladder
  • Undifferentiated carcinoma of the bladder
Conditions that may be covered by SOP (further information required)
  • Bladder cancer
Conditions excluded from SOP
  • Carcinoid of the bladder#
  • Hodgkin's lymphoma of the bladder*
  • Malignant neoplasm of the prostate*
  • Malignant neoplasm of the urethra*
  • Non-Hodgkin lymphoma of the bladder*
  • Soft tissue sarcoma of the bladder*

* another SOP applies

#Non-SOP condition

Clinical onset

The most common presentation is painless haematuria (blood in the urine), either visible or detected on testing.  However, haematuria in most cases is due to a benign cause.  Other symptoms of bladder cancer are also similar to those of benign urinary disorders.  Delays in diagnosis are common.  Clinical onset may coincide with the time of diagnosis, or it may be possible to backdate clinical onset based on preceding symptoms or findings.

Clinical worsening

The only SOP worsening factor is for inability to obtain appropriate clinical management.  Bladder cancer has a very variable course and prognosis.  It is amenable to treatment if found early.  A delay in appropriate treatment could result in worsening of the condition.  Establishing whether worsening beyond the normal course of the disease has occurred will generally require expert medical opinion. 

 

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/m/malignant-neoplasm-bladder-b029-c67-d090/rulebase-malignant-neoplasm-bladder/treatment-systemic-cyclophosphamide-or-systemic-ifosfamide

Last amended